Fibrodysplasia ossificans progressiva-When bone suddenly forms within muscle

被引:0
|
作者
Grossmann, Nadine Z. [1 ,2 ]
Hildebrandt, Susanne [1 ,2 ]
Morhart, Rolf [3 ]
Kallinich, Tilmann [4 ]
Semler, Oliver [5 ,6 ]
Knaus, Petra [1 ,2 ,7 ]
机构
[1] Free Univ Berlin, Inst Chem Biochem, Berlin, Germany
[2] Univ Med Berlin, Berlin Brandenburg Sch Regenerat Therapies, Charite, Berlin, Germany
[3] Klinikum Garm Partenkirchen, Kinder & Jugendmedizin, Garmisch Partenkirchen, Germany
[4] Univ Med Berlin, Padiatr Rheumatol, Charite, Berlin, Germany
[5] Univ Cologne, Med Fak, Cologne, Germany
[6] Uniklin Koln, Klinik Poliklin Kinder & Jugendmed, Cologne, Germany
[7] Free Univ Berlin, Inst Chem & Biochem, Thielallee 63, D-14195 Berlin, Germany
关键词
Fibrodysplasia ossificans progressiva; Heterotopic ossification; Myositis ossificans; Soft tissue swelling; Congenital hallux valgus; FOP;
D O I
10.1007/s00112-023-01816-5
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Fibrodysplasia ossificans progressiva (FOP) is a very rare genetic condition caused by a point mutation in the ACVR1 gene. There are two clinical features indicative of FOP: 1) a congenital malformation of the great toe(s), similar to a hallux valgus and 2) unexplained soft tissue swelling usually resulting in heterotopic ossifications (HO). Early recognition of these two features is very important to avoid misdiagnosis and incorrect treatment and to ensure the correct diagnosis as early as possible by genetic testing of the ACVR1 gene. As soon as this diagnosis is available it is advisable for the affected person to see a FOP specialist and to establish contact with the German patient organization "FOP e. V.".All invasive interventions should be strictly avoided, as they can trigger irreversible HO. The complexity and systemic course of FOP requires the establishment and collaboration of an interdisciplinary team for optimal care of affected individuals. Treatment of FOP flare-ups and subsequent ossification is currently symptomatic according to the international guidelines of the ICC on FOP (www.iccfop.org). Targeted treatment approaches in current clinical trials aim to influence the bone morphogenetic protein (BMP) signalling pathway at multiple levels to halt or slow disease progression.While more than 95% of all affected individuals have the classical point mutation, a small number of affected individuals have variant mutations. Each of these mutations leads to hypersensitivity and overactivation of the ACVR1 receptor and results in an increased BMP signalling response.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Characterization of bone morphogenetic protein 4 receptor in fibrodysplasia ossificans progressiva
    Lanchoney, TF
    Olmsted, EA
    Shore, EM
    Gannon, FA
    Rosen, V
    Zasloff, MA
    Kaplan, FS
    CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 1998, (346) : 38 - 45
  • [22] Bone morphogenetic protein-4 regulation in fibrodysplasia ossificans progressiva
    Olmsted, EA
    Kaplan, FS
    Shore, EM
    CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2003, (408) : 331 - 343
  • [23] Heterotopic Bone Formation Induced by Bone Morphogenetic Protein Signaling: Fibrodysplasia Ossificans Progressiva
    Katagiri, Takenobu
    JOURNAL OF ORAL BIOSCIENCES, 2010, 52 (01): : 33 - 41
  • [24] Osteochondromas in fibrodysplasia ossificans progressiva: a widespread trait with a streaking but overlooked appearance when arising at femoral bone end
    A. Morales-Piga
    J. Bachiller-Corral
    P. González-Herranz
    M. Medrano-SanIldelfonso
    J. Olmedo-Garzón
    G. Sánchez-Duffhues
    Rheumatology International, 2015, 35 : 1759 - 1767
  • [25] Osteochondromas in fibrodysplasia ossificans progressiva: a widespread trait with a streaking but overlooked appearance when arising at femoral bone end
    Morales-Piga, A.
    Bachiller-Corral, J.
    Gonzalez-Herranz, P.
    Medrano-SanIldelfonso, M.
    Olmedo-Garzon, J.
    Sanchez-Duffhues, G.
    RHEUMATOLOGY INTERNATIONAL, 2015, 35 (10) : 1759 - 1767
  • [26] Deregulated Bone Morphogenetic Protein Receptor Signaling Underlies Fibrodysplasia Ossificans Progressiva
    de Gorter, David J. J.
    Jankipersadsing, Vishant
    ten Dijke, Peter
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (27) : 4087 - 4092
  • [27] Fibrodysplasia Ossificans Progressiva in a Maine Coon Cat with Prominent Ossification in Dorsal Muscle
    Yabuzoe, Atsushi
    Yokoi, Shin-ichi
    Sekiguchi, Maiko
    Momoi, Yasuyuki
    Ide, Kaori
    Nishifuji, Koji
    Iwasaki, Toshiroh
    JOURNAL OF VETERINARY MEDICAL SCIENCE, 2009, 71 (12): : 1649 - 1652
  • [28] The Occurrence of an Aneurismal Bone Cyst and Multiple Osteochondromas in a Patient With Fibrodysplasia Ossificans Progressiva
    Dec, Wojciech
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2009, 32 (01): : 88 - 89
  • [29] 99mTc-MDP Bone Scan Findings in Fibrodysplasia Ossificans Progressiva
    Gupta, Nitin
    Verma, Ritu
    Belho, Ethel Shangne
    Dey, Sudip
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (09) : 694 - 695
  • [30] Question: Bone marrow transplant for fibrodysplasia ossificans progressiva - Has the hour arrived?
    Altschuler, EL
    Emerson, SG
    Kaplan, FS
    CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2001, (392) : 450 - 455